Bertil Lindmark
Venture Partner XGEN Venture
Dr. Bertil Lindmark is a Venture Partner at XGEN Venture and a seasoned biopharma leader with nearly 30 years of experience across respiratory, immunology, and oncology drug development. He has held senior global roles at AstraZeneca and Almirall, contributing to multiple successful drug approvals and launches, including landmark respiratory therapies.
Formerly, Chief Medical Officer at Vicore Pharma and Galecto Inc and Chairman of Aqilion AB, Dr. Lindmark continues to drive innovation in fibrosis and inflammatory diseases. His experience spans translational research, clinical development, and strategic leadership, including IPOs, major funding events, and acquisitions. With a PhD in molecular epidemiology from Lund University, he brings a strong scientific and commercial perspective to advancing next-generation therapies for patients with high unmet need, including fibrotic lung diseases.
Seminars
Defining Value, Differentiation & De-Risking in a Competitive Landscape
As the IPF field advances beyond proof-of-concept and into an era of increasing mechanistic diversity, the question is no longer whether IPF drug development is viable, but what makes an asset truly investable.
With new mechanisms emerging and the bar for differentiation rising, clarity on what constitutes a compelling therapeutic story has never been more critical. This panel brings together investors, strategic pharma, and M&A leaders to define what “good” looks like, and what it doesn’t, in today’s IPF landscape.
Key Discussion Points:
- What Builds Conviction Early? What efficacy signals, durability data, mechanistic rationale, safety profile, and translational evidence are required at preclinical and early clinical stages to generate real investor confidence?
- Differentiation vs. Incrementalism? In a field moving beyond simply slowing FVC decline, what level of clinical impact, biomarker validation, or combination rationale is needed to stand out from the noise?
- De-Risking, Timing & Strategic Positioning? How do investors evaluate first-in-class versus best-in-class strategies? What role do trial design, regulatory strategy, management credibility, and partnership readiness play in investment and acquisition decisions?
